NASDAQ
21.11.25 | 21:59
1,170 US-Dollar
+13,59 % +0,140
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.11. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings | 1 | Benzinga.com | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 14.11. | Piper Sandler lowers TELA Bio stock price target to $1.25 on soft Q3 results | 1 | Investing.com | ||
| 14.11. | TELA Bio stock price target lowered to $5 at Citizens on lower ASP | 1 | Investing.com | ||
| 14.11. | Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet | 1 | Seeking Alpha | ||
| 13.11. | Earnings call transcript: Tela Bio Q3 2025 sees revenue growth but EPS miss | 1 | Investing.com Deutsch | ||
| 13.11. | TELA Bio prices $13 million offering of common stock and warrants | 1 | Investing.com | ||
| 13.11. | TELA Bio prices $13M registered direct offering of common stock, pre-funded warrants | 2 | Seeking Alpha | ||
| 13.11. | TELA Bio, Inc.: TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| 13.11. | TELA Bio meldet 9 % Umsatzwachstum im 3. Quartal und passt Prognose für 2025 an | 1 | Investing.com Deutsch | ||
| 13.11. | TELA Bio GAAP EPS of -$0.19 beats by $0.02, revenue of $20.7M misses by $1.08M | 6 | Seeking Alpha | ||
| 13.11. | TELA Bio, Inc.: TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility | 66 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 04.11. | TELA Bio, Inc.: TELA Bio to Announce Third Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 03.11. | TELA Bio beruft William Plovanic in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 03.11. | TELA Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.10. | TELA Bio appoints healthcare leader Betty Jo Rocchio to board | 1 | Investing.com | ||
| 09.10. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.10. | TELA Bio, Inc.: TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran | 68 | GlobeNewswire (Europe) | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 12.08. | Tela Bio reiterates $85M-$88M 2025 revenue target as international expansion accelerates | 1 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 20,115 | -3,43 % | Biologische Fertigung im Fokus - wie NurExone, Moderna und Lonza von der Industrialisierung regenerativer Therapien profitieren könnten | ||
| SAREPTA THERAPEUTICS | 15,200 | -1,01 % | FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,900 | -1,66 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| MYRIAD GENETICS | 6,400 | 0,00 % | Myriad Genetics auf der Wolfe Research Konferenz: Strategischer Wandel in der Krebsversorgung | ||
| PHIO PHARMACEUTICALS | 1,130 | -5,04 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress | King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,404 | +0,89 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| VIR BIOTECHNOLOGY | 5,685 | +2,16 % | Vir Biotechnology, Inc.: Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference | Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday... ► Artikel lesen | |
| RAPT THERAPEUTICS | 23,000 | -4,17 % | RAPT Therapeutics, Inc.: RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | CytoMed acquires TC BioPharm's gamma delta T cell technology | ||
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +13,59 % bei einem Aktienkurs von 1,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.